By Fineline Cube 
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for Adzynma (apadamtase alfa/cinaxadamtase alfa), a recombinant ADAMTS13 protein drug indicated for on-demand or prophylactic enzyme replacement therapy (ERT) in children and adults with congenital thrombotic thrombocytopenic purpura (cTTP).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full marketing approval |
| Product | Adzynma (apadamtase alfa/cinaxadamtase alfa) |
| Indication | On-demand or prophylactic ERT for cTTP in pediatric and adult patients |
| Approval Date | 25 Jun 2026 |
| Significance | First and only recombinant ADAMTS13 therapy approved in China |
Drug Profile & Mechanism of Action
- Molecule: Recombinant ADAMTS13 protein therapeutic
- Target: ADAMTS13 enzyme deficiency in cTTP patients
- Innovation: First recombinant ADAMTS13 drug available in China, specifically designed to replenish deficient plasma ADAMTS13 activity
- Mechanism: Regulates metabolism of von Willebrand factor (vWF) multimers, reducing or eliminating formation of vWF-platelet microthrombi
- Clinical Benefit: Lowers risk of acute/subacute TTP events and associated clinical manifestations
Clinical Significance
cTTP is an ultra-rare, life-threatening blood disorder characterized by severe deficiency of the ADAMTS13 enzyme, leading to uncontrolled formation of microthrombi in small blood vessels. Prior to this approval, Chinese cTTP patients had limited therapeutic options, often relying on plasma-based therapies with variable efficacy and safety profiles.
Adzynma represents a targeted, precision medicine approach that addresses the root cause of cTTP by directly replacing the missing enzymatic activity. This approval establishes a new standard of care for Chinese cTTP patients, offering predictable dosing, consistent product quality, and reduced risk of plasma-derived complications.
Market Impact & Outlook
- China cTTP Landscape: Estimated several hundred cTTP patients nationwide based on global prevalence data of 1-10 cases per million population
- Competitive Position: Adzynma becomes the first and currently only recombinant ADAMTS13 therapy available in China
- Strategic Value: Strengthens Takeda’s rare disease portfolio in China, complementing existing hematology assets
- Pricing & Access: Expected premium pricing reflecting orphan drug status and significant clinical benefit; discussions underway with provincial reimbursement authorities
- Global Context: Adzynma previously received approvals in the US, EU, and other major markets, demonstrating consistent regulatory acceptance worldwide
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations for Adzynma. Actual results may differ due to risks including market adoption, reimbursement decisions, and competitive dynamics.-Fineline Info & Tech